AV-203: Phase I data

An open-label, U.S. Phase I trial in 22 patients with metastatic or advanced solid tumors showed that 2, 5, 9, 14 and 20 mg/kg doses of IV AV-203 every 2 weeks led to 8 cases of stable disease. AV-203 was well generally tolerated with diarrhea and reduced appetite reported as the most common treatment-related adverse events. The recommended Phase II dose is 20 mg/kg IV AV-203 every 2 weeks. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...